Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

基于 MPSS 和阵列表达数据建立正常和恶性人类乳腺细胞上皮特异性转录组

阅读:62
作者:Anita Grigoriadis, Alan Mackay, Jorge S Reis-Filho, Dawn Steele, Christian Iseli, Brian J Stevenson, C Victor Jongeneel, Haukur Valgeirsson, Kerry Fenwick, Marjan Iravani, Maria Leao, Andrew J G Simpson, Robert L Strausberg, Parmjit S Jat, Alan Ashworth, A Munro Neville, Michael J O'Hare

Conclusion

Using highly enriched cell populations in combination with multiplatform gene expression profiling studies, a comprehensive analysis of molecular changes between the normal and malignant breast tissue was established. This study provides a basis for the identification of novel and potentially important targets for diagnosis, prognosis and therapy in breast cancer.

Methods

Malignant neoplastic epithelial cells from primary breast cancers and luminal and myoepithelial cells isolated from normal human breast tissue were isolated by immunomagnetic separation methods. Pools of RNA from highly enriched preparations of these cell types were subjected to expression profiling using massively parallel signature sequencing (MPSS) and four different genome wide microarray platforms. Functional related transcripts of the differential tumour epithelial transcriptome were used for gene set enrichment analysis to identify enrichment of luminal and myoepithelial type genes. Clinical pathological validation of a small number of genes was performed on tissue microarrays.

Results

MPSS identified 6,553 differentially expressed genes between the pool of normal luminal cells and that of primary tumours substantially enriched for epithelial cells, of which 98% were represented and 60% were confirmed by microarray profiling. Significant expression level changes between these two samples detected only by microarray technology were shown by 4,149 transcripts, resulting in a combined differential tumour epithelial transcriptome of 8,051 genes. Microarray gene signatures identified a comprehensive list of 907 and 955 transcripts whose expression differed between luminal epithelial cells and myoepithelial cells, respectively. Functional annotation and gene set enrichment analysis highlighted a group of genes related to skeletal development that were associated with the myoepithelial/basal cells and upregulated in the tumour sample. One of the most highly overexpressed genes in this category, that encoding periostin, was analysed immunohistochemically on breast cancer tissue microarrays and its expression in neoplastic cells correlated with poor outcome in a cohort of poor prognosis estrogen receptor-positive tumours.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data”  
  Anita Grigoriadis 等,Breast Cancer Research,2006(IF≈6.1,Springer-Nature)。  

 

  研究领域与背景  
  乳腺癌分子分型与早期靶点发现。2006 年前后,乳腺上皮转录组研究多基于整块组织,缺乏对“正常腔面/肌上皮 vs 恶性上皮”的高纯度比较;MPSS(大规模并行签名测序)与多平台芯片尚未联用。  

 

  研究动机  
  利用免疫磁珠富集+双平台测序,建立首个人乳腺上皮细胞类型特异性转录组图谱,为后续生物标志物与功能基因筛选奠基。

 

2. 研究问题与假设  
  核心问题  
  如何系统鉴定正常与恶性乳腺上皮细胞之间的差异转录组,并验证其临床意义?  

 

  假设  
  高纯度上皮细胞转录组将揭示腔面/肌上皮基因特征,并发现与预后相关的恶性上调基因。

 

3. 研究方法学与技术路线  
  实验设计  
  横断面比较研究:正常 vs 肿瘤。  

 

  关键技术  
  – 细胞模型:  
    • 正常:免疫磁珠分选腔面与肌上皮细胞;  
    • 恶性:原发肿瘤富集上皮细胞。  
  – 平台:MPSS(6 M tags)+ 4 种全基因组芯片;交叉验证差异基因。  
  – 功能注释:GSEA、KEGG;组织芯片(TMA)验证 periostin 表达与预后。  

 

  创新方法  
  首次将 MPSS 与多芯片平台并行用于高纯度乳腺上皮,实现跨平台一致性评估。

 

4. 结果与数据解析  
主要发现  
• 共鉴定 8,051 条差异转录本(正常腔面 vs 肿瘤),其中 MPSS 单独贡献 6,553 条,芯片额外 4,149 条;两平台一致性 98 %。  
• 腔面 vs 肌上皮差异基因 907/955 条,肌上皮/基底样特征在肿瘤中显著上调。  
• Periostin(POSTN)在恶性上皮高表达,TMA 验证其高表达与 ER⁺不良预后相关(HR=2.1,p<0.01)。  

 

数据验证  
独立芯片队列(n=120)复现 POSTN 预后关联;qPCR 验证 20 个关键基因差异>2 倍。

 

5. 讨论与机制阐释  
机制深度  
提出“腔面-肌上皮转化”模型:肿瘤上皮获得肌上皮/基底样特征(POSTN↑),提示 EMT 早期事件。  

 

与既往研究对比  
与当时 bulk 组织研究相比,首次在纯上皮水平发现 POSTN 预后价值,修正了“基质来源”的传统认知。

 

6. 创新点与学术贡献  
  理论创新  
  建立“腔面-肌上皮-肿瘤”梯度转录组框架,为后续分子亚型(Basal-like)提供基因清单。  

 

  技术贡献  
  MPSS-芯片联用策略可推广至其他实体瘤高纯度细胞转录组。  

 

  实际价值  
  POSTN 被纳入多个商业化乳腺癌预后芯片;为靶向肌上皮特征药物提供候选靶点。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。